Why More AI is Not Always Better for Clinical Programming
October 20, 2026
Clinical programming teams are under pressure to deliver faster while maintaining quality, traceability, and compliance across increasingly complex studies, data standards, specifications, and outputs. Artificial intelligence (AI) can help address this pressure, but does every programming task actually need AI?
In regulated clinical development environments, the goal is not to replace existing methods with a general-purpose AI layer. It is to build controlled workflows that combine agentic AI, rule-based systems, deterministic execution, and human oversight.
Clinical programming also operates within a broader development workflow. Outputs from biostatistics, data management, clinical programming, and medical writing depend on each other, and decisions made in one area can affect downstream quality, timelines, and submission readiness. AI adoption therefore cannot be limited to isolated use cases such as code generation or document drafting. Organizations need to assess the full workflow, identify where AI can remove friction, and determine where processes should be redesigned rather than simply automated.
Using AI where it adds value
Clinical programming involves tasks with very different levels of complexity. Some require interpretation, reasoning, and decision-making. Others follow predictable rules and established standards. For example, creating program headers, converting metadata, or performing straightforward variable mappings may be handled more efficiently through validated macros, templates, or rule-based systems. Complex transformations, ambiguous specifications, and tasks requiring contextual interpretation may benefit more from AI reasoning.
A hybrid architecture allows AI agents to orchestrate workflows and handle complex tasks while deterministic systems execute repeatable operations. This can improve predictability, reduce unnecessary AI processing, and make outputs easier to validate.
Token efficiency should be built into the architecture
As AI models become more sophisticated, their computational processing can increase. Advanced reasoning models can consume significantly more tokens to complete tasks, introducing additional costs and latency.
For clinical programming teams looking to scale AI adoption, they need to assess whether the additional processing delivers enough value to justify its cost. Sending every task through a large reasoning model, particularly with extensive context, is unlikely to be the most efficient approach. Instead, organizations should evaluate each step in the workflow and determine the most appropriate execution method. Deterministic processes can handle standardized activities, while AI reasoning is reserved for tasks that genuinely require it. This approach shifts the focus from maximizing AI usage to maximizing useful work per unit of inference, creating a more sustainable foundation for AI-enabled programming.
Better AI outputs begin with better inputs
One of the biggest challenges in AI-supported programming isn’t necessarily the model itself. It is the quality of the specifications and data on which the model depends. Incomplete requirements, inconsistent metadata, missing assumptions, and unclear transformation logic can all introduce errors, regardless of how capable the AI system is.
Consider a recurring discrepancy caused by incomplete codelists in programming specifications. The immediate response might be to improve the AI model or introduce additional output validation. But a more effective solution could be to implement an upstream check comparing source-data codelists with those in the specifications before programming begins.
Rather than relying solely on AI to detect or correct errors, organizations can use implementation insights to strengthen the underlying quality system. Benchmarking AI-generated outputs against trusted historical results, investigating discrepancies, and involving subject matter experts in root-cause analysis are essential to this process. The objective is not simply faster code generation. It is a more reliable workflow in which quality is designed into the process.
Scaling AI requires governance and human expertise
Even the most sophisticated AI architecture cannot compensate for weak governance or unclear accountability. In regulated clinical development, AI-supported workflows must remain transparent, reproducible, and auditable. This requires documented standards, validated components, appropriate data protections, and clearly defined human oversight.
Organizations also need to evaluate AI performance against their own programming requirements. Public benchmarks may not adequately reflect the complexity of clinical datasets, specifications, and regulatory expectations. Internal evaluations should consider not only accuracy but also latency, cost, transparency, and the effort required to review outputs.
Equally important is preparing teams to work differently. Programmers and other clinical development professionals need to understand where AI performs reliably, where it may fail, and which outputs require closer scrutiny. Human expertise remains essential, but its focus increasingly shifts toward defining requirements, resolving ambiguity, validating critical decisions, and managing risk.
The path forward: A new operating model
Successfully integrating AI into clinical programming requires more than selecting the right models or tools. It requires an operating model that combines AI reasoning with established programming methods, incorporates quality controls throughout the workflow, and can adapt as the technology evolves.
Rather than automating every possible activity, organizations should focus on where AI can deliver measurable improvements in efficiency and quality while maintaining the standards required in regulated clinical development. The goal should not be to lock the organization into a fixed platform. AI technology changes too quickly for that approach. A more sustainable strategy is to build an operating model that can continuously adopt better technology while maintaining governance, security, quality, and compliance.
Interested in learning more?
For a deeper discussion of token-efficient clinical programming, hybrid agentic AI architectures, and practical implementation considerations, watch the on-demand webinar featuring Nicolas Rouille and Manuel Cossio:
Register today!Subscribe to our newsletter
Nicolas Rouillé
Vice President, Applied AI, Biometrics
Nicolas Rouillé is Senior Director, Statistical Programming for Cytel’s Projects Based Services (PBS) unit in Europe. He oversees statistical programming for the “Analysis” projects, with responsibilities including line management and ensuring project quality, timelines, and budgets. He began his journey at Cytel in 2013, helping establish the company’s first European office in Geneva. His work involved expanding operations, recruiting and developing teams, enhancing processes, and establishing strategic vendor partnerships.
Read full employee bio
Manuel Cossio
Head of AI Solutions, Real-World Evidence, Value, and Access
Manuel Cossio is Head of AI Solutions, Real-World Evidence, Value, and Access at Cytel. Manuel is an AI engineer with over a decade of experience in healthcare AI research and development. He currently leads the creation of generative AI solutions aimed at optimizing clinical trials, focusing on hierarchical multi-agent systems with multistage data governance and human-in-the-loop dynamic behavior control.
Manuel has an extensive research background with publications in computer vision, natural language processing, and genetic data analysis. He is a registered Key Opinion Leader at the Digital Medicine Society, a member of the ISPOR Community of Interest in AI, a Generative AI evaluator for the EU Commission, and an AI researcher at UB-UPC- Barcelona Supercomputing Center.
He holds an M.Sc. in Translational Medicine from Universitat de Barcelona, a Master of Engineering in AI from Universitat Politècnica de Catalunya, and a M.Sc. in Neuroscience from Universitat Autònoma de Barcelona.
Read full employee bioClaim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.